Issuu on Google+

Publicacions 2010 Oncologia Mèdica

1. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, et al. Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging-Defined, Locally Advanced Rectal Cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 28 (5): 859865, 2010 IF: 17,157 2. Sanjuán, G. Escaramís, S. Vidal-Sicart, M. Illa, G. Zanón, J. Pahisa, S. Rubí, M. Velasco, G. Santamaría, B. Farrús, M. Muñoz, Y. García, PL Fernández, F. Pons. Predicting NonSentinel Lymph Node Status in Breast Cancer Patients with Sentinel Lymph Node Involvement: Evaluation of Two Scoring Systems. Breast J 16: 134-140, 2010 IF: 2,091 3. Gómez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M, Gimferrer JM, Marrades R, Lomeña F. Incidence of occult mediastinal node involvement in CN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. Eur J Cardiothorac Surg 37: 1168-1174, 2010 IF: 2.397 4. Maio M, Mackiewicz A, Testori A, Treftzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F. Phase II Randomized Study of Thymosin Alpha 1, Interferon Alpha, or Both, in Combination with Dacarbazine in Patients with Malignant Melanoma. J Clin Oncol 28: 1780-1787, 2010 IF: 17,157 5. Rojo F, Gracia E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Bellosillo B, Rovira A, Marsoni S, Gascón P, et al. Pharmacodynamic trial of nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody, in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 16: 2474-2482, 2010 IF: 6.488 6. Sanjuan X, Salas A, Lloreta J, Manchon Walsh P. Colorectal cancer Oncoguia: surgical pathology report guidelines. Clin Transl Oncol 12: 211-214, 2010 IF: 1.146 7. Manchon Walsh P, Borras JM, Ferro T, Espinas JA. Colorectal cancer Oncoguia. Clin Transl Oncol 12: 188-211, 2010 IF: 1.146 8. Le Tourneau C, Stathis A, Vidal L, Malcolm J. Moore, and Lillian L. Siu. Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials. J Clin Oncol, 28: 1401-1407, 2010 IF: 17,157 9. Navarro S, Vaquero E, Maurel J, et al. Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part I). Med Clin (Barc) 134(14):643-55, 2010


Publicacions 2010 Oncologia Mèdica

IF: 1,258 10. Navarro S, Vaquero E, Maurel J, et al. Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part II). Med Clin (Barc) 134: 692-702, 2010 IF: 1,258 11. GASTRIC (Global advanced/adjuvant stomach tumor research international collaboration) Group, Paoletti X, Obak, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303: 1729-1737, 2010 IF: 31.718 12. Tusquets I, García-Estévez L, Adrover E, Calvo L, Alvarez I, García-Mata J, Fernandez Y, Margueli M, Segui MA, Rodríguez C, Rodríguez Lescure A, Colomer R, Gascón P, et al. Current controversies in the managament of breast cancer. Clin Transl Oncol 12: 278286, 2010 IF: 1.146 13. Casas F, Borras JM, Ferrer F, Guanyabens N, Gutierrez del Pozo R, Leon C, López Torrecilla J, Mellado B, et al. Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. Clin Transl Oncol 12: 346-355, 2010 IF: 1.146 14. Steinberg M, McCarthy W, et al and investigators of the multicenter study of hydroxyurea in Sickle cell anemia and MSH patients follow-up. The risks and benefits of long-term use of hydrowyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 85: 403-408, 2010 IF: 2.126 15. Gascon P, Uwe F, Fritz S, Einmahl S, Balser S, Muenzberg M. Development of a new G-CSF product based on biosimilarity assessment. Annals Oncol 21: 1419- 1429, 2010 IF:4,935 16. Martin-Broto J, Gutierrez A, Garcia del Muro X, Lopez Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) study. Ann Oncol 21: 1552-1557, 2010 IF: 4,935 17. Molina R, Auge JM, Farrus B, Zanón G, Pahisa J, Muñoz M, Torne A, Filella X, Escudero JM, Fernandez P, Velasco M. Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Cancer Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer. Clin Chem 56: 1148-1157, 2010 IF: 5.579 18. Molina R, Augé JM, Escudero JM, Filella X, Zanon G, Pahisa J, Farrús B, Muñoz M, Velasco M. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in


Publicacions 2010 Oncologia Mèdica

patients with locoregional breast cancer: prognostic value. Tumour Biol 31: 171-180 2010 IF: 2,238 19. Maurel J, Martins AS, Poveda A, López-Guerrero JA, Cubedo R, Casado A, MartínezTrufero J, Ayuso JR, López-Pousa A, García-Albeniz X, Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish group for research on sarcomas. Cancer 116: 3692-3701, 2010 IF: 5.6 20. Anton A, Lluch A, Casado A, Provencio M, Muñoz M, Lao J, Bermejo B, Paules AB, Gayo J, Martin M. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Anticancer Res 30: 2255-2261, 2010. IF: 1.39 21. Almendro V, Garcia-Recio S, Gascón P. Tyrosine kinase receptor transactivation associated to G-protein-coupled receptors. Current Drug Targets 11: 1169-1180, 2010 IF: 4.187 22. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28: 3965-3972, 2010 IF: 17,157 23. Visa L, Caballero M, Grau JJ. Response to metronomic chemotherapy in a metastatic adenoidcystic carcinoma of the parotid gland. Acta Otorrinolaringol Esp 61: 452-454, 2010 24. Garcia-Alvarez A, Sitges M, Garcia-Albéniz X, et al. Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib. Int J Cardiol 139(2):29-31, 2010 IF: 2,878 25. Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Baselga J. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Ann Oncol 21(7):1442-1447, 2010 IF: 4,935 27. Gascon P, Fuhr U, Sörgel F, Einmahl S, Balser S, Muenzberg M. Development of a new G-CSF product based on biosimilarity assessment. Annals Oncol 21(7):1419-1429 201 IF: 4,935 28. International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. Prognostic factors in patients with


Publicacions 2010 Oncologia Mèdica

metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28(33):4906-4911, 2010 (Mellado) IF: 17,157 29. Arnal-Estapé A, Tarragona M, Morales M, Guiu M, Nadal C, Massagué J, Gomis RR. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPβ isoforms. Cancer Res 70(23): 9927-9936, 2010 IF: 7.543 30. Visa L, Arance A, Puig S, Malvehi J. Perspectiva de la quimioterapia y la inmunoterapia en el tratamiento del melanoma metastático. Clínica Dermatológica. Vol. X, Nº: 1/2010 31. Adet A, Miquel R, Bombi JA, Gines A, Fernández Esparrach G, De Juan C, Ayuso JR, Maurel J, Castells A, Fernández-Cruz L, Navarro S. Incidence and characteristics of pancreatic cystic neoplasms. Gastroenterol Hepatol 33(8):563-568, 2010 32. Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, RodríguezLescure A, Große R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A, for the GEICAM 9805 Investigators. Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. N Engl J Med 363 (23): 2200-2210, 2010 IF: 47.050 33. Muñoz M, Pahisa J, Caparrós F, Vidal-Sicart S. Sentinel lymph node and neoadjuvant therapy in breast cancer. Rev Esp Med Nucl 29(6):319-320, 2010 IF: 0.765 34. Ametller E, Garcia-Recio S, Domizziana C, Mayordomo C, Fernandez-Nogueira P, Carbó N, Pastor-Arroyo E, Gascón P, Almendro V. Tumor promoting effects of CD95 signalling in chemoresistant cells. Mol Cancer 9: 161, 2010 IF: 5.36 35. Ahmadiyeh N, Pomerantz M, Grisanzio C, Herman P, Jia L, Almendro V, He H, Brown M, X. Shirley Liu, MattDavis , Caswell J, Beckwith C, Hills A, MacConaill L, Coetzee G, Regan M, Freedman M. 8q24 prostate, breast, and colon cancer risk loci show tissuespecific longrange interaction with MYC. Proc Natl Acad Sci USA. 107: 9742-9746, 2010 IF: 9.432 36. Gonzalez-Roca E, Garcia-Albéniz X, Rodríguez-Mulero S, Gomis RR, Kornacker K, Auer H. Accurate expression profiling of very small cell populations. Plos One 5 (12): e14418, 2010 IF: 4.351 37. Reguart N, Cardona AF, Rosell R. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. Cancer Manag Res 2: 143-156, 2010


Publicacions 2010 Oncologia Mèdica

38. Estévez LG, Alvarez I, Seguí MA, Muñoz M, Margelí M, Miró C, Rubio C, Lluch A, Tusquets I. Current perspectives of treatment of ductal carcinoma in situ. Cancer Treat Rev 36: 507-517, 2010 IF: 5.295 39. Trabal J, Leves P, Forga M, Maurel J. Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr Hosp 25: 736-740, 2010 IF: 1.065 40. Gascon P, Pirker R, Del Mastro L, Durrwell L. Effects of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy: Results of a Phase II Study. Annals Oncol 21 (10): 2029-2039, 2010 IF: 4,935

IF TOTAL 2010= 259.464


Publicacions 2010